TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares are experiencing a notable surge on the US stock charts today, rising 13.22% to reach $2.57 following the announcement of a pivotal research collaboration. This agreement positions TCBP to advance its efforts in developing a treatment for Monkeypox, signaling a strategic move in response to ongoing public health challenges.
TC Biopharm’s Collaboration with a Leading Researcher
Dr. Carlos Maluquer de Motes, a Reader and Principal Investigator at the University of Surrey in the United Kingdom, is involved in the partnership. The Pirbright Institute, which is well-known for its proficiency in researching viral infections that spread from animals to people, is associated with Dr. Maluquer de Motes.
He has a PhD in Virology from the University of Barcelona and has conducted important research in prominent universities like the University of Cambridge, Imperial College London, and the University of Pennsylvania. He has concentrated on the ways that herpesviruses evade the immune system and the relationship between innate immunity and the vaccinia virus.
TCBP: Addressing Viral Infections
Given the difficulties caused by worldwide pandemics, TC Biopharm is aware of how important gamma delta T-cells are for triggering efficient immune responses to viral infections. Research indicates that these cells are essential not only for preventing infections but also for improving clinical outcomes in affected patients.
TC Biopharm aims to leverage its lead therapeutic, TCB008, to enhance the immune response by bolstering gamma delta T-cells, potentially improving treatment for Monkeypox and other infectious diseases.
Future Directions in Prophylactic Applications
TC Biopharm is also exploring the prophylactic potential of TCB008, aiming to support high-risk patients who are immune-compromised or elderly. The company envisions utilizing TCB008 as an adjunct therapy in hospital settings, thereby addressing the vulnerability of patients whose immune systems are weakened.
Given his stellar record in infectious illness research, TC Biopharm has decided to follow Dr. Maluquer de Motes’ research strategy following in-depth discussions with subject-matter specialists. TCBP’s dedication to combating new viral dangers has advanced significantly with this partnership.
